Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2014 · 10-Q
Revenue$1.09M$1.09M+11.3% vs Q2 2013 Net Income-$926.97K-$926.97KN/M vs Q2 2013 EPS Diluted-$0.02-$0.02N/M vs Q2 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$845,981N/M Free Cash Flowderived-$858,359— Margins · derivedGross margin-3.1%+13.1 pt vs Q2 2013
Operating margin-96.2%+16.5 pt vs Q2 2013
Net margin-85.4%+32.9 pt vs Q2 2013
ended Dec 31, 2013 · filed Feb 14, 2014 · 45 d after period end